1887

Abstract

Normal immunocompetent mice are not susceptible to non-adapted filoviruses. There are therefore two strategies available to establish a murine model of filovirus infection: adaptation of the virus to the host or the use of genetically modified mice that are susceptible to the virus. A number of knockout (KO) strains of mice with defects in either their adaptive or innate immunity are susceptible to non-adapted filoviruses. In this study, A129 α/β −/− interferon receptor-deficient KO mice, strain A129 IFN-α/β −/−, were used to determine the lethality of a range of filoviruses, including Lake Victoria marburgvirus (MARV), Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Reston ebolavirus (REBOV) and Côte d’Ivoire ebolavirus (CIEBOV), administered by using intraperitoneal (IP) or aerosol routes of infection. One hundred percent mortality was observed in all groups of KO mice that were administered with a range of challenge doses of MARV and ZEBOV by either IP or aerosol routes. Mean time to death for both routes was dose-dependent and ranged from 5.4 to 7.4 days in the IP injection challenge, and from 10.2 to 13 days in the aerosol challenge. The lethal dose (50 % tissue culture infective dose, TCID) of ZEBOV for KO mice was <1 TCID ml when administered by either the IP or aerosol route of infection; for MARV the lethal dose was <1 TCID ml by the IP route of infection and <10 TCID ml by the aerosol route. In contrast, there was no mortality after infection with SEBOV or REBOV by either IP or aerosol routes of infection; all the mice lost weight (~15 % loss of group mean body weight with SEBOV and ~7 % with REBOV) but recovered to their original weights by day 14 post-challenge. There was no mortality in mice administered with CIEBOV via the IP route of infection and no clinical signs of infection were observed. The progression of disease was faster following infection with ZEBOV than with MARV but ultimately both viruses caused widespread infection with high titres of the infectious viruses in multiple organs. Histopathological observations were consistent with other animal models and showed widespread organ damage. This study suggests that MARV and ZEBOV are more virulent when administered via the IP route rather than by aerosol infection, although both are highly virulent by either route. The KO mouse may provide a useful model to test potential antiviral therapeutics against wild-type filoviruses.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.036210-0
2012-01-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/1/8.html?itemId=/content/journal/jmm/10.1099/jmm.0.036210-0&mimeType=html&fmt=ahah

References

  1. Barrette R. W., Metwally S. A., Rowland J. M., Xu L., Zaki S. R., Nichol S. T., Rollin P. E., Towner J. S., Shieh W.-J. other authors 2009; Discovery of swine as a host for the Reston ebolavirus. Science 325:204–206 [View Article][PubMed]
    [Google Scholar]
  2. Bazhutin N. B., Belanov E. F., Spiridonov V. A., Voǐtenko A. V., Krivenchuk N. A., Krotov S. A., Omel’chenko N. I., Tereshchenko A. Iu., Khomichev V. V. 1992; [The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys]. Vopr Virusol 37:153–156 (in Russian) [PubMed]
    [Google Scholar]
  3. Bente D., Gren J., Strong J. E., Feldmann H. 2009; Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2:12–17 [View Article][PubMed]
    [Google Scholar]
  4. Bowen E. T. W., Platt G. S., Lloyd G., Raymond R. T., Simpson D. I. H. 1980; A comparative study of strains of Ebola virus isolated from southern Sudan and northern Zaire in 1976. J Med Virol 6:129–138 [View Article][PubMed]
    [Google Scholar]
  5. Bray M. 2001; The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 82:1365–1373[PubMed]
    [Google Scholar]
  6. Bray M. 2002; Filoviridae. In Clinical Virology, 2nd edn. pp. 875–890 Edited by Richman D. R., Whitley R. J., Hayden F. G. Washington, DC: American Society for Microbiology;
    [Google Scholar]
  7. Bray M., Paragas J. 2002; Experimental therapy of filovirus infections. Antiviral Res 54:1–17 [View Article][PubMed]
    [Google Scholar]
  8. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. 1998; A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178:651–661 [View Article][PubMed]
    [Google Scholar]
  9. Bray M., Hatfill S., Hensley L., Huggins J. W. 2001; Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 125:243–253 [View Article][PubMed]
    [Google Scholar]
  10. CDC 2009; CDC Emergency Preparedness and Response website, Bioterrorism Agents/Diseases, by Category. Accessed 7th August 2009.. Available at http://emergency.cdc.gov/agent/agentlist-category.asp
  11. Druett H. A. 1969; A mobile form of the Henderson apparatus. J Hyg (Lond) 67:437–448 [View Article][PubMed]
    [Google Scholar]
  12. Groseth A., Feldmann H., Strong J. E. 2007; The ecology of Ebola virus. Trends Microbiol 15:408–416 [View Article][PubMed]
    [Google Scholar]
  13. Guyton A. C. 1947; Measurement of the respiratory volumes of laboratory animals. Am J Physiol 150:70–77[PubMed]
    [Google Scholar]
  14. Harper G. J., Morton J. D. 1962; A method for measuring the retained dose in experiments on airborne infection. J Hyg (Lond) 60:249–257 [View Article][PubMed]
    [Google Scholar]
  15. Henderson D. W. 1952; An apparatus for the study of airborne infection. J Hyg (Lond) 50:53–68 [View Article][PubMed]
    [Google Scholar]
  16. Jaax N., Jahrling P., Geisbert T., Geisbert J., Steele K., McKee K., Nagley D., Johnson E., Jaax G., Peters C. 1995; Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669–1671 [View Article][PubMed]
    [Google Scholar]
  17. Johnson E., Jaax N., White J., Jahrling P. 1995; Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 76:227–236[PubMed]
    [Google Scholar]
  18. Kuhn J. H. 2008 In Filoviruses: a Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies pp. 23–37 Edited by Calisher C. H. Wien & New York: Springer;
    [Google Scholar]
  19. Lever M. S., Nelson M., Stagg A. J., Beedham R. J., Simpson A. J. 2009; Experimental acute respiratory Burkholderia pseudomallei infection in BALB/c mice. Int J Exp Pathol 90:16–25 [View Article][PubMed]
    [Google Scholar]
  20. Lub M. Iu., Sergeev A. N., P’iankova O. G., P’iankov O. V., Petrishchenko V. A., Kotliarov L. A. 1995a; [Clinical-virusological characteristics of disease in guinea pigs, infected by the Marburg virus aerogenically]. Vopr Virusol 40:119–121 (in Russian) [PubMed]
    [Google Scholar]
  21. Lub M. Iu., Sergeev A. N., P’iankov O. V., P’iankova O. G., Petrishchenko V. A., Kotliarov L. A. 1995b; [Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route]. Vopr Virusol 40:158–161 (in Russian) [PubMed]
    [Google Scholar]
  22. May K. R., Harper G. J. 1957; The efficiency of various liquid impinger samplers in bacterial aerosols. Br J Ind Med 14:287–297[PubMed]
    [Google Scholar]
  23. Piercy T. J., Smither S. J., Steward J. A., Eastaugh L., Lever M. S. 2010; The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J Appl Microbiol 109:1531–1539[PubMed]
    [Google Scholar]
  24. Reed L., Muench H. A. 1938; A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493–497
    [Google Scholar]
  25. Sanchez A., Geisbert T. W., Feldmann H. 2007; Marburg and Ebola viruses. In Fields Virology, 5th edn. vol. 1 pp. 1409–1448 Edited by Knipe D. M., Howley P. M. Philadelphia: Lippincott Williams and Wilkins;
    [Google Scholar]
  26. Thomas R. J., Webber D., Sellors W., Collinge A., Frost A., Stagg A. J., Bailey S. C., Jayasekera P. N., Taylor R. R. other authors 2008; Characterization and deposition of respirable large- and small-particle bioaerosols. Appl Environ Microbiol 74:6437–6443 [View Article][PubMed]
    [Google Scholar]
  27. Warfield K. L., Alves D. A., Bradfute S. B., Reed D. K., VanTongeren S., Kalina W. V., Olinger G. G., Bavari S. 2007; Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J 4:108 [View Article][PubMed]
    [Google Scholar]
  28. Warfield K. L., Bradfute S. B., Wells J., Lofts L., Cooper M. T., Alves D. A., Reed D. K., VanTongeren S. A., Mech C. A., Bavari S. 2009; Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 83:6404–6415 [View Article][PubMed]
    [Google Scholar]
  29. WHO 1978; Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56:247–270[PubMed]
    [Google Scholar]
  30. WHO 2009; Outbreak news. Ebola Reston in pigs and humans, Philippines. Wkly Epidemiol Rec 84:49–50
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.036210-0
Loading
/content/journal/jmm/10.1099/jmm.0.036210-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error